Bioventus Inc. (BVS) stock

BVSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Nov 2, 2026Score 14/3033% below fair value

$10.86−0.13 (-1.18%)

Close on Nov 12, 2026Market cap $913.24MP/E 13.6Yield –

Bioventus total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Bioventus's total debt was $229.83M at Sep 26, 2026. For fiscal 2025 it was $293.95M, down 12.4% from the year before. The highest annual figure on record is $418.07M in fiscal 2022.

Annual total debt

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$293.95M	-12.4%
FY2024	Dec 31, 2024	$335.63M	-15.0%
FY2023	Dec 31, 2023	$394.85M	-5.6%
FY2022	Dec 31, 2022	$418.07M	+16.9%
FY2021	Dec 31, 2021	$357.68M	+89.9%
FY2020	Dec 31, 2020	$188.38M	–

Quarterly total debt

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 26, 2026	$229.83M	-28.8%
Q2 FY2026	Jun 27, 2026	$248.45M	-27.2%
Q1 FY2026	Mar 28, 2026	$272.08M	-21.3%
Q4 FY2025	Dec 31, 2025	$293.95M	-12.4%
Q3 FY2025	Sep 27, 2025	$322.58M	-15.9%
Q2 FY2025	Jun 28, 2025	$341.24M	-11.0%
Q1 FY2025	Mar 29, 2025	$345.93M	-11.6%
Q4 FY2024	Dec 31, 2024	$335.63M	-15.0%
Q3 FY2024	Sep 28, 2024	$383.59M	-2.8%
Q2 FY2024	Jun 29, 2024	$383.28M	-0.7%
Q1 FY2024	Mar 30, 2024	$391.24M	-12.2%
Q4 FY2023	Dec 31, 2023	$394.85M	-5.6%
Q3 FY2023	Sep 30, 2023	$394.62M	-7.0%
Q2 FY2023	Jul 1, 2023	$385.89M	+3.2%
Q1 FY2023	Apr 1, 2023	$445.59M	+21.0%
Q4 FY2022	Dec 31, 2022	$418.07M	+16.9%
Q3 FY2022	Oct 1, 2022	$424.40M	+139.2%
Q2 FY2022	Jul 2, 2022	$373.98M	+106.5%
Q1 FY2022	Apr 2, 2022	$368.33M	+99.4%
Q4 FY2021	Dec 31, 2021	$357.68M	+89.9%
Q3 FY2021	Oct 2, 2021	$177.44M	–
Q2 FY2021	Jul 3, 2021	$181.08M	–
Q1 FY2021	Apr 3, 2021	$184.73M	–
Q4 FY2020	Dec 31, 2020	$188.38M	–